Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Which lens implant delivers sharper sight after cataract surgery?

NCT ID NCT07768475

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 17, 2026 · Last updated Aug 18, 2026 · Updated 1 time

Summary

This trial compares two types of intraocular lenses implanted during cataract surgery: the Clareon PanOptix and the Tecnis Odyssey. About 266 adults with cataracts in both eyes will receive one lens type in each eye, and researchers will measure how well they see at various distances and how satisfied they are. The goal is to see if one lens offers better visual outcomes or patient satisfaction than the other.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Intraocular lens implants: Clareon PanOptix and Tecnis Odyssey
What this could lead to
If one lens proves better, it could guide surgeons in choosing implants that give sharper vision and higher satisfaction after cataract surgery.
What could go wrong
This is a single-center study, and results may not apply to all patients. Individual outcomes vary, and neither lens may show a clear advantage.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

266 people

The number who actually took part.

Started

Jul 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Willing and able to understand and sign informed consent 2. Willing and able to participate with all study testing 3. Adult patient diagnosed with age-related cataracts bilaterally 4. Planned bilateral cataract removal by phacoemulsification with bilateral implantation of the Clareon PanOptix/ Clareon PanOptix Toric or Tecnis Odyssey IOL/ Tecnis Odyssey IOL Toric (T3/4 or DRT150, DRT225) 5. Best monocular corrected distance visual acuity expected to be 0.1 logMAR (Snellen 20/25) or better in both eyes postoperatively as determined by surgeon 6. Residual astigmatism expected to be ≤ 0.50 diopters in both eyes postoperatively as determined by surgeon (After using either toric IOL or arcuate incision with laser) 7. Normal ocular findings aside from cataract Exclusion Criteria: 1. HOA greater than 0.4 μm within central 4 mm 2. Corneal dystrophies, degenerations, irregular astigmatism or any corneal abnormality aside from regular astigmatism deemed to be of clinical significance by the surgeon. 3. Any pathologic conditions that might affect ease of cataract removal (pseudoexfoliation, posterior polar, etc) as determined by surgeon 4. Strabismus with or without amblyopia in either eye 5. Previous history of any ocular surgery including corneal refractive surgery 6. Presence of any macular disease, history of retinal detachment, or posterior segment abnormality deemed to be of clinical significance by the surgeon. 7. Presence of glaucoma 8. Presence of any acute or chronic systemic disease that would confound the results of this study as determined by the surgeon (e.g. uncontrolled diabetes, immunocompromise, autoimmune disease, etc). 9. Any planned simultaneous/combined procedures at time of cataract surgery (e.g. MIGs). 10. Any subjects with intraoperative complications, including vitreous loss, posterior capsular rupture, zonular dialysis, decentered or tilted IOL, diffuse corneal epithelial defect, and use of iris hooks or expanders, will be excluded from analysis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Age-related cataract are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hyperspeed LASIK

    Rowland Heights, California, 91748, United States

  • Parkhurst Nuvision

    San Antonio, Texas, 78229, United States

  • Seeta Eye Center

    Poughkeepsie, New York, 12603, United States

  • Texas Eye and Laser Center

    Hurst, Texas, 76054, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.